Combination Therapy for DLBCL, in Phase 2b Trial, Named Orphan Drug by FDA
News
The U.S. Food and Drug Administration (FDA) has designated the combination of TG-1101 and TGR-1202 an Orphan Drug as a potential treatment for diffuse large B-cell lymphoma (DLBCL). The combination recently received Orphan Drug designation ... Read more